Last updated: April 19, 2022
Sponsor: Fondazione Epatocentro Ticino
Overall Status: Active - Recruiting
Phase
N/A
Condition
Liver Disease
Liver Disorders
Hepatic Fibrosis
Treatment
N/AClinical Study ID
NCT03146910
SASL39 - Swiss PBC Cohort
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- diagnose of Primary biliary cholangitis (according to EASL Clinical PracticeGuidelines: management of cholestatic liver diseases).
- Subjects with isolated anti-mitochondrial antibodies and/or isolated PBC-specificanti-nuclear antibodies are also included
- Patients/subjects aged at least 18 years and living in Switzerland are included
Exclusion
Exclusion Criteria:
- N/A
Study Design
Total Participants: 500
Study Start date:
February 15, 2017
Estimated Completion Date:
December 31, 2022
Study Description
Connect with a study center
Fondazione Epatocentro Ticino
Lugano, Ticino 6900
SwitzerlandActive - Recruiting
Gastroenterologie und Hepatologie, Clarunis - Universitäres Bauchzentrum Basel
Basel, 4031
SwitzerlandActive - Recruiting
Inselspital
Bern, 3010
SwitzerlandActive - Recruiting
Hôpitaux Universitaires de Genève, Service de Gastroentérologie & Hépatologie, Département des Spécialités
Geneve, 1205
SwitzerlandActive - Recruiting
Kantonsspital Baselland
Liestal, 4410
SwitzerlandActive - Recruiting
EOC Ospedale Regionale di Lugano - Italiano
Lugano, 6900
SwitzerlandActive - Recruiting
Kantonsspital St.Gallen
Sankt Gallen, 9007
SwitzerlandActive - Recruiting
Kantonsspital Winterthur
Winterthur, 8400
SwitzerlandActive - Recruiting
Universitätsspital Zürich
Zurich, 8091
SwitzerlandActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.